NeuroSense adds new ALS biomarker data to planned Canadian PrimeC submission

• NeuroSense Therapeutics moved its Canadian PrimeC filing target to March 2027 from December 2026 to include new ALS trial data.
• Newly disclosed analysis showed PrimeC reduced a neuronal injury biomarker more than placebo, with stronger effects in participants with higher baseline functionality.
• The submission will combine published Phase 2b PARADIGM results with the new analysis and additional unpublished trial data; statistical analyses remain underway.
• Health Canada raised no concerns about the revised timing; its standard review target is approximately 300 calendar days following submission acceptance.
• The filing would be PrimeC’s first marketing application, targeting approximately 4,000 Canadians with ALS in a market recording approximately 1,000 new diagnoses annually.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611020900PR_NEWS_USPR_____IO86656) on November 02, 2026, and is solely responsible for the information contained therein.